Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma

American Journal of Hematology

Volumn 89, Issue 6, 2014, Pages 575-580

  El Galaly, Tc ^a,b   Mylam, Karen Juul ^c   Bøgsted, Martin ^a,d   Brown, Peter ^e   Rossing, Maria ^e   Gang, Anne Ortved ^f   Haglund, Anne ^a   Arboe, Bente ^g   Clausen, Michael Roost ^b   Jensen, Paw ^a   Pedersen, Michael ^f   Bukh, Anne ^b   Jensen, Bo Amdi ^c   Poulsen, Christian Bjørn ^g   D'Amore, Francesco ^b   Hutchings, Martin ^e  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e Rigshospitalet   (Denmark)

^f Mental Health Services CPH   (Denmark)

^g ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGGRESSIVE NON HODGKIN LYMPHOMA; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DEATH; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SELF REPORT; SYMPTOM;

AGED; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 84900844110     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23688     Document Type: Article

References (42)

1. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
2. d'Amore F, Relander T, Lauritzsen GF, et al. Upfront autologuos stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093-3099.
3. Eichenauer DA, Engert A, Dreyling M, Group EGW. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (Suppl 6):vi55-58.
4. Tilly H, Vitolo U, Walewski J, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 (Suppl 7):vii78-82.
5. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol 1997;15:1123-1130.
6. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 1997;314:343-346.
7. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991;9:1196-1203.
8. Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21:2262-2266.
9. Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006;24:4116-4122.
10. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241.
11. Statens Serum Instistut [internet]. Copenhagen. Tariffs from the Danish Diagnosis Related Grouping System (DRG) 2013. Available from: http://www.ssi.dk/Sundhedsdataogit/Sundhedsoekonomi/Takster/Takster%202013.aspx. Accessed November 21, 2013.
12. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-230.
13. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-1996.
14. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
15. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
16. Voss SD, Chen L, Constine LS, et al. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: A report from the Children's Oncology Group. J Clin Oncol 2012;30:2635-2640.
17. Dryver ET, Jernstrom H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: The routine CT scan is of little value. Br J Cancer 2003;89:482-486.
18. Bestawros A, Foltz L, Srour N, et al. Patients' and physicians' roles in detecting recurrent Hodgkin lymphoma following complete remission. Ann Oncol 2013;24:1359-1363.
19. Lin TL, Kuo MC, Shih LY, et al. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 2012;91:1741-1745.
20. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909-113.
21. Abel GA, Vanderplas A, Rodriguez MA, et al. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database. Leuk Lymphoma 2012;53:1113-1116.
22. Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123-125.
23. Elis A, Blickstein D, Klein O, et al. Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies. Am J Hematol 2002;69:41-44.
24. Thompson CA, Maurer MJ, Ghesquieres H, et al. Utility of post-therapy surveillance scans in DLBCL. J Clin Oncol 2013;31 (Suppl); Abstract 8504.
25. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-1787.
26. Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 2013;88:400-405.
27. El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: Status in a single center. Leuk Lymphoma 2011;52:597-603.
28. Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 2013;109:312-317.
29. Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: A clinical and economic analysis. Cancer 2010;116:3835-3842.
30. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2012;97:931-936.
31. Goldschmidt N, Or O, Klein M, et al. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 2011;90:165-171.
32. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 2006;28:711-714.
33. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-130.
34. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006;28:300-306.
35. Hodgson DC, Grunfeld E, Gunraj N, Del Giudice L. A population-based study of follow-up care for Hodgkin lymphoma survivors: Opportunities to improve surveillance for relapse and late effects. Cancer 2010;116:3417-3425.
36. Petrausch U, Samaras P, Haile SR, et al. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010;21:1694-1698.
37. Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up? Ann Oncol 2010;21:1053-1057.
38. Hartridge-Lambert SK, Schoder H, Lim RC, et al. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. Cancer 2013;119:1203-1209.
39. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009;169:2078-2086.
40. Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009;251:175-184.
41. Pingali SR, Jewell S, Havlat L, et al. Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. J Clin Oncol 2013;31 (Suppl); Abstract 8505.
42. Dann EJ, Berkahn L, Mashiach T, et al. Hodgkin lymphoma patients in first remission: Routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. Br J Haematol, December 7 2013, epub ahead of print.